Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Dyne Therapeutics Inc Market Cap
From what 8 stock analysts predict, the share price for Dyne Therapeutics Inc (DYN) might increase by 57.57% in the next year. This is based on a 12-month average estimation for DYN. Price targets go from $50 to $66. The majority of stock analysts believe DYN is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 8 Wall Street analysts have assignedDYN 4 buy ratings, 4 hold ratings, and 0 sell ratings. This means that analysts expect Dyne Therapeutics Inc to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on DYN. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of DYN.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Andrew Fein HC Wainwright & Co. | Buy | $55 | Reiterates | Sep 4, 2024 |
| Francois Brisebois Oppenheimer | Outperform | $55 | Reiterates | Sep 3, 2024 |
| Paul Matteis Stifel | Buy | $66 | Maintains | Aug 16, 2024 |
| Debjit Chattopadhyay Guggenheim | Buy | $50 | Maintains | Aug 15, 2024 |
| Michael Ulz Morgan Stanley | Overweight | $52 | Maintains | Aug 14, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $55 | Maintains | Aug 13, 2024 |
| Edward Tenthoff Piper Sandler | Overweight | $53 | Maintains | Aug 13, 2024 |
| Tessa Romero JP Morgan | Overweight | $43 | Maintains | Jul 9, 2024 |
| Keay Nakae Chardan Capital | Buy | $42 | Maintains | May 21, 2024 |
Jefferies | Buy | $42 | Maintains | May 20, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $48 | Maintains | May 20, 2024 |
| Keay Nakae Chardan Capital | Buy | $31 | Maintains | May 6, 2024 |
| Francois Brisebois Oppenheimer | Outperform | $47 | Reiterates | May 6, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $36 | Reiterates | May 3, 2024 |
| Michael Ulz Morgan Stanley | Overweight | $40 | Initiates | Apr 30, 2024 |
| Francois Brisebois Oppenheimer | Outperform | $47 | Reiterates | Mar 26, 2024 |
| Keay Nakae Chardan Capital | Buy | $31 | Maintains | Mar 8, 2024 |
| Debjit Chattopadhyay Guggenheim | Buy | $37 | Maintains | Mar 7, 2024 |
| Edward Tenthoff Piper Sandler | Overweight | $29 | Maintains | Mar 6, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $36 | Reiterates | Mar 6, 2024 |
When did it IPO
2020
Staff Count
152
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. John G. Cox M.B.A.
Market Cap
$3.45B
In 2023, DYN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that DYN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 17 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Dyne Therapeutics, Inc. (NASDAQ: DYN). Affected investors can visit bgandg.com/DYN for more information.
Why It Matters - Potential claims against Dyne Therapeutics may indicate legal issues or financial instability, raising concerns about the company's stock performance and risk for current and prospective investors.
Tue, 17 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Pomerantz LLP is investigating claims for investors of Dyne Therapeutics, Inc. (NASDAQ: DYN) as of September 17, 2024.
Why It Matters - The investigation may indicate potential legal issues for Dyne Therapeutics, which could impact the company’s stock performance and investor confidence.
Sun, 15 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating Dyne Therapeutics (NASDAQ:DYN) for potential securities law violations, including possible false statements and undisclosed information impacting investors.
Why It Matters - The investigation into Dyne Therapeutics for potential securities law violations could lead to legal repercussions, impacting stock performance and investor confidence.
Mon, 16 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating Dyne Therapeutics (NASDAQ:DYN) for potential securities law violations, including possible false statements and undisclosed information affecting investors.
Why It Matters - Investors face potential losses if Dyne Therapeutics is found to have misled them, impacting stock value and investor confidence. Legal ramifications could also arise, affecting future performance.
Tue, 17 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating Dyne Therapeutics (NASDAQ:DYN) for potential securities law violations related to false or misleading statements made by the company.
Why It Matters - The investigation into Dyne Therapeutics for potential securities law violations could lead to legal liabilities and affect the company's stock price, impacting investor confidence and returns.
Sun, 15 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Dyne Therapeutics, Inc. (NASDAQ:DYN). Affected investors are encouraged to seek more information.
Why It Matters - Potential claims against Dyne Therapeutics could indicate legal or financial issues, impacting the company's stock performance and investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
